- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03620578
DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152)
A Phase II Study Evaluating the Effect of DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Patients With Newly Diagnosed High Grade B Cell Lymphoma (HGBL) With MYC and BCL2 and/or BCL6 Rearrangements
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The dismal prognosis of DH-DLBCL patients following standard therapy with R-CHOP (overall survival at 2 years 35% for MYC+ vs 61% for MYC- patients) justifies upfront new treatment approaches.
Attempts have been made to improve prognosis of DH-DLBCL patients with intensified chemotherapy schemes like DA-EPOCH-R, standard treatment of Burkitt lymphoma with high dose multi-agent chemotherapy (R-CODOX-M/R-IVAC) and autologous stem cell transplantation. These treatment schedules seem to prolong disease-free survival (DFS), but relapses do often occur and improved OS has not been achieved. The investigators hypothesize to increase the number of patients in complete remission with DA-EPOCH-R to 65% as compared to 50% for R-CHOP. DA-EPOCH-R is a well-known scheme for the treatment of patients with Burkitt Lymphoma, and is one of the treatment arms of the Hemato-Oncologie voor Volwassenen Nederland (HOVON) 127 protocol. For DH-DLBCL patients the investigators expect that it will improve the complete remission (CR) rate and prolong DFS as compared to R-CHOP as has been shown in several retrospective studies. It is also clear from these studies that relapses still occur and that OS is not improved by chemotherapy only.
The investigators expect to induce deeper remission with DA-EPOCH-R providing the opportunity for nivolumab to consolidate complete remission, prolong DFS, or to induce conversion of minimal residual disease (MRD) positivity to MRD negativity.
A new approach underlying this proposal is to enhance anti-tumor immune responses. Malignancies with MYC aberrations were long thought to be independent of immune responses. However, recently it was shown that MYC expressing lymphoma and leukaemia mouse and human cell lines upregulate programmed death-ligand 1 (PDL1) ("don't find me" signal) and CD47 ("don't eat me" signal) expression. Inactivation of MYC enhanced tumour immune responses in vivo in mice. Moreover, a subset of DLBCL does express PDL1.
No correlation with MYC rearrangements or protein expression has been described in these studies; however, these data suggest that tumours with MYC overexpression may be especially vulnerable to treatment with immune check point inhibitors, providing the rationale for treatment with nivolumab.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Antwerpen, Belgium
- BE-Antwerpen-ZNASTUIVENBERG
-
Leuven, Belgium
- BE-Leuven-UZLEUVEN
-
-
-
-
-
Almere, Netherlands
- NL-Almere-FLEVOZIEKENHUIS
-
Amersfoort, Netherlands
- NL-Amersfoort-MEANDERMC
-
Amsterdam, Netherlands
- NL-Amsterdam-AMC
-
Amsterdam, Netherlands
- NL-Amsterdam-VUMC
-
Den Bosch, Netherlands
- NL-Den Bosch-JBZ
-
Den Haag, Netherlands
- NL-Den Haag-HAGA
-
Eindhoven, Netherlands
- NL-Eindhoven-MAXIMAMC
-
Enschede, Netherlands
- NL-Enschede-MST
-
Goes, Netherlands
- NL-Goes-ADRZ
-
Groningen, Netherlands
- NL-Groningen-UMCG
-
Hoofddorp, Netherlands
- NL-Hoofddorp-SPAARNEGASTHUIS
-
Hoorn, Netherlands
- NL-Hoorn-DIJKLANDERHOORN
-
Leeuwarden, Netherlands
- NL-Leeuwarden-MCL
-
Leiden, Netherlands
- NL-Leiden-LUMC
-
Maastricht, Netherlands
- NL-Maastricht-MUMC
-
Nijmegen, Netherlands
- NL-Nijmegen-RADBOUDUMC
-
Rotterdam, Netherlands
- NL-Rotterdam-ERASMUSMC
-
Rotterdam, Netherlands
- NL-Rotterdam-MAASSTADZIEKENHUIS
-
Sittard, Netherlands
- NL-Sittard-Geleen-ZUYDERLAND
-
Tilburg, Netherlands
- NL-Tilburg-ETZ
-
Utrecht, Netherlands
- NL-Utrecht-UMCUTRECHT
-
Zwolle, Netherlands
- NL-Zwolle-ISALA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Inclusion Criteria for DA-EPOCH-R induction:
- High-grade B-cell lymphoma, with MYC in combination with BCL2 and/or BCL6 rearrangements as assessed by fluorescence in situ hybridization (FISH) according to the WHO 2016 classification including high-grade B-cell lymphoma with MYC and BCL2 rearrangements, transformed from previously untreated FL.
- Age ≥ 18 year.
- Patient started with or has received one course of full dose R-CHOP. [Reversed R-CHOP (cyclophosphamide, vincristine and doxorubicin on day 5) is allowed; local radiation or short course (max 7 days) of steroids (max 100 mg/day) before R-CHOP is allowed. Mini-R-CHOP is not allowed].
- World Health Organization (WHO) performance status 0-3 during or after the first R-CHOP cycle.
- Ann Arbor stage II-IV at diagnosis.
- 18F-FDG PET scan and contrast enhanced CT-scan performed within 21 days before start first cycle of R-CHOP.
- Measurable disease: on contrast enhanced CT-scan at least 1 lesion/node with a long axis of >1.5 cm and at least one 18F-FDG avid lesion.
- Negative pregnancy test at study entry.
- Patient is willing and able to use adequate contraception until 6 months post last treatment administration.
- Written informed consent.
- Patient is capable of giving informed consent.
Inclusion criteria for Nivolumab consolidation:
- Complete metabolic response on end of induction 18F-FDG PET-CT assessed with the Deauville response criteria
- Patient has completed at least R-CHOP plus four cycles of DA-EPOCH-R induction treatment
Exclusion Criteria:
Exclusion Criteria for DA-EPOCH-R induction:
- All histopathological diagnoses other than DH/TH-HGBL (like testicular large B-cell lymphoma or primary mediastinal B-cell lymphoma) according to WHO 2016 classification.
- Known history of indolent lymphoma previously treated with immunochemotherapy.
- Inadequate renal function or creatinine clearance < 30 mL/min (after rehydration). Creatinine clearance (CrCl) may be calculated by Cockcroft -Gault formula: CrCl = (140 - age [in years]) x weight [kg] (x 0.85 for females) (0.815 x serum creatinine [μmol/L])
- Inadequate hepatic function: bilirubin > 3 times upper limit of normal (ULN) (total) except patients with Gilbert's syndrome as defined by > 80% unconjugated bilirubin.
- Inadequate hematological function: absolute neutrophil count (ANC) < 1.0x109/L or platelets < 75x109 /L before R-CHOP unless lymphoma related.
- Central nervous system (CNS) localization of the lymphoma. Cerebrospinal fluid (CSF) analysis before start of treatment is only necessary in case of suspicion of CNS localization.
- Female subject pregnant or breast-feeding.
- History of active malignancy during the past 5 years with the exception of basal carcinoma of the skin or stage 0 cervical carcinoma.
- Active symptomatic ischemic heart disease, myocardial infarction, or congestive heart failure within the past year. In case of cardiac history, an echo or multigated acquisition (MUGA) should be obtained and left ventricular ejection fraction (LVEF) should exceed 40% to be eligible.
- Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, cancer, etc.) that would jeopardize the patient's ability to receive the regimen with reasonable safety.
- HIV positivity.
- Active Hepatitis B or C infection as defined by positive serology and transaminitis. Non-active Hepatitis B carriers may be included if protected
- Severe pulmonary dysfunction (CTCAE grade III-IV).
- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Prior treatment with an anti-PD1, anti-PDL1, anti-PDL2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.
- Severe neurological or psychiatric disease.
- Current participation in another clinical trial interfering with this trial.
- Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- Claustrophobia precluding PET-CT.
Exclusion criteria for Nivolumab consolidation:
- Inadequate renal function or creatinine clearance < 30 mL/min (after rehydration). Creatinine clearance may be calculated by Cockcroft -Gault formula: CrCl = (140 - age [in years]) x weight [kg] (x 0.85 for females) (0.815 x serum creatinine [μmol/L])
- Inadequate hepatic function: bilirubin > 3 times ULN (total) except patients with Gilbert's syndrome as defined by > 80% unconjugated bilirubin.
- Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DA-EPOCH-R followed by Nivolumab
5 cycles of DA-EPOCH-R protocol induction, followed with one year Nivolumab consolidation for end-of-induction patients who are in complete metabolic response
|
5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12 months DFS from Nivolumab consolidation registration
Time Frame: 12 months
|
12 months DFS (defined as time from registration for consolidation to disease relapse or death, whichever comes first) of patients in CMR as assessed by end of DA-EPOCH-R treatment 18F-Fludeoxyglucose Positron Emission Tomography- Computed Tomography (18F-FDG PET-CT)
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete metabolic response (CMR) rate on 18F-FDG PET-CT after DA-EPOCH-R
Time Frame: at 18 weeks
|
CMR rate on 18F-FDG PET-CT after DA-EPOCH-R
|
at 18 weeks
|
18 months Progression-Free Survival (PFS)
Time Frame: 18 months
|
18 months PFS (defined as time from registration to disease progression, relapse or death, whichever comes first)
|
18 months
|
18 months OS
Time Frame: 18 months
|
18 months OS (defined as time from registration until death from any cause; patients still alive or lost to follow up are censored at the date they were last known to be alive) of all patients
|
18 months
|
12 months OSc
Time Frame: 12 months
|
12 months overall survival under consolidation (OSc), defined as time from registration for consolidation until death from any cause.
Patients still alive or lost to follow up are censored at the date they were last known to be alive
|
12 months
|
Rate of CTCAE grade >=2 toxicities
Time Frame: During 70 weeks treatment + 100 additional days during follow up
|
Rate of CTCAE grade >=2 toxicities
|
During 70 weeks treatment + 100 additional days during follow up
|
consolidation MRD conversion
Time Frame: 12 months
|
Rate of conversion to MRD negativity during consolidation
|
12 months
|
predictive value of mid-treatment 18F-FDG PET-CT
Time Frame: 2 months
|
Assessment of the predictive value of mid-treatment 18F-FDG PET-CT with respect to CMR at the end of DA-EPOCH-R therapy
|
2 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: M. ED Chamuleau, MD PhD, VUmc / HOVON
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, B-Cell
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- HO152
- 2017-003631-12 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, B-Cell
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Nathan DenlingerBristol-Myers SquibbRecruitingB-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditionsUnited States
-
AstraZenecaRecruitingFollicular Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | B-cell Non Hodgkin LymphomaKorea, Republic of, United States, Japan, Australia, Taiwan
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Massachusetts General HospitalVarian Medical SystemsRecruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
-
University of ChicagoMerck Sharp & Dohme LLCRecruitingLymphoma | Lymphoma, B-Cell | B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University of NebraskaBristol-Myers SquibbRecruitingFollicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditionsUnited States
-
Curocell Inc.RecruitingHigh-grade B-cell Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Primary Mediastinal Large B-Cell Lymphoma (PMBCL) | Transformed Follicular Lymphoma (TFL) | Refractory Large B-cell Lymphoma | Relapsed Large B-cell LymphomaKorea, Republic of
Clinical Trials on DA-EPOCH-R followed by Nivolumab
-
Dana-Farber Cancer InstituteGenentech, Inc.RecruitingRichter SyndromeUnited States
-
Nordic Lymphoma GroupHelsinki University Central Hospital; Aarhus University HospitalRecruitingLymphoma, Large B-Cell, DiffuseDenmark, Norway, Sweden, Finland
-
Elena N.ParovichnikovaRecruiting
-
Shandong Provincial HospitalRecruitingMantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | B-cell NonHodgkin LymphomaChina
-
Fudan UniversityTerminated
-
Pharmacyclics LLC.Celgene CorporationCompletedDiffuse Large B Cell Lymphoma Refractory | Diffuse Large B Cell Lymphoma RelapsedUnited States
-
Shandong Provincial HospitalRecruitingMantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsChina
-
National Research Center for Hematology, RussiaNational Research Center for HematologyRecruiting
-
Fujian Medical UniversityActive, not recruitingDiffuse Large B-cell LymphomaChina
-
University Hospital, Clermont-FerrandUniversité d'Auvergne; Tza Nou - Maison médicale pour enfants et adolescentes... and other collaboratorsCompleted